<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588456</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 31415, 822967</org_study_id>
    <nct_id>NCT02588456</nct_id>
  </id_info>
  <brief_title>Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-label pilot study to determine the feasibility and&#xD;
      safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors&#xD;
      expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as &quot;CART22&quot;&#xD;
      cells) administered in split fractions, in adult patients with relapsed or refractory B-cell&#xD;
      acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated due to lack of efficacy&#xD;
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART22 cells</intervention_name>
    <description>CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form must be obtained prior to any research procedure.&#xD;
&#xD;
          2. Relapsed or refractory B-cell ALL:&#xD;
&#xD;
             a. 1st or greater BM relapse OR b. Any marrow relapse after allogeneic HSCT and &gt; 100&#xD;
             days from transplant OR c. For patients with refractory disease: i. &lt; 60 years old&#xD;
             that have not achieved a CR after &gt; 2 or more chemotherapy regimens ii. &gt;60 years old&#xD;
             that have not achieved a CR after 1 prior chemotherapy regimen d. Patients with Ph+&#xD;
             ALL are eligible if they are intolerant to or have failed tyrosine kinase inhibitor&#xD;
             therapy.&#xD;
&#xD;
             e. Patients with CNS3 disease will be eligible if CNS disease is responsive to&#xD;
             therapy.&#xD;
&#xD;
          3. Documentation of CD22 expression on malignant cells at relapse.&#xD;
&#xD;
          4. Adequate organ function defined as:&#xD;
&#xD;
               1. Creatinine &lt; 1.6 mg/dl&#xD;
&#xD;
               2. ALT/AST &lt; 3x upper limit of normal range&#xD;
&#xD;
               3. Direct bilirubin &lt;2.0 mg/dl&#xD;
&#xD;
               4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea,&#xD;
                  pulse oxygen &gt; 92% on room air, and DLCO &gt; 40% (corrected for anemia)&#xD;
&#xD;
               5. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA&#xD;
&#xD;
          5. Evidence of disease by standard morphologic or by MRD criteria.&#xD;
&#xD;
          6. Male or female age ≥ 18 years.&#xD;
&#xD;
          7. ECOG Performance Status that is either 0 or 1.&#xD;
&#xD;
          8. No contraindications for leukapheresis.&#xD;
&#xD;
          9. Subjects of reproductive potential must agree to use acceptable birth control methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active hepatitis B or active hepatitis C.&#xD;
&#xD;
          2. HIV Infection.&#xD;
&#xD;
          3. Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification.&#xD;
&#xD;
          4. Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on&#xD;
             medical management within two weeks of enrollment.&#xD;
&#xD;
          5. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.&#xD;
&#xD;
          6. Concurrent use of systemic steroids or immunosuppressant medications. Recent or&#xD;
             current use of inhaled steroids or physiologic replacement with hydrocortisone is not&#xD;
             exclusionary. For additional details regarding use of steroid and immunosuppressant&#xD;
             medications.&#xD;
&#xD;
          7. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that&#xD;
             might increase the risk of CNS toxicity.&#xD;
&#xD;
          8. Pregnant or nursing (lactating) women.&#xD;
&#xD;
          9. Receipt of a prior investigational study agent within 4 weeks prior to enrollment.&#xD;
             *Note- patients who have received anti-CD19 CART cells (e.g. CART19/CTL019) on an&#xD;
             investigational study where cell infusion occurred greater than 4 weeks before the&#xD;
             screening visit are NOT excluded.&#xD;
&#xD;
         10. Patients with a known history or prior diagnosis of optic neuritis or other&#xD;
             immunologic or inflammatory disease affecting the central nervous system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noelle Frey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

